Marion Subklewe

Marion Subklewe

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 253 publications

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology
Published: June 18, 2026

Pre-treatment T cell features and immune-milieu characteristics shape treatment-induced exhaustion and resistance to Blinatumomab in B-cell acute lymphoblastic leukemia.

Pre-treatment T cell features and immune-milieu characteristics shape treatment-induced exhaustion and resistance to Blinatumomab in B-cell acute lymphoblastic leukemia.

Journal: Frontiers in immunology
Published: May 30, 2026

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.

Journal: Bone marrow transplantation
Published: April 12, 2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Journal: Blood
Published: April 01, 2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Journal: Haematologica
Published: March 20, 2026

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

Journal: Leukemia
Published: March 18, 2026

Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features.

Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features.

Journal: Neurology
Published: March 17, 2026

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

Journal: The New England journal of medicine
Published: March 04, 2026

Feasibility and safety of rapid glofitamab ramp-up.

Feasibility and safety of rapid glofitamab ramp-up.

Journal: Leukemia
Published: January 20, 2026

Flow cytometry in hematological diagnostics - step by step

Flow cytometry in hematological diagnostics - step by step

Journal: Deutsche medizinische Wochenschrift (1946)
Published: January 20, 2026

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Journal: Transplantation and cellular therapy
Published: January 05, 2026

Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.

Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 05, 2026
Showing 1-12 of 253

Last Updated: 09/26/2026